News | May 27, 2009

Stereotactic Body Radiation Therapy Helps Manage Lung Cancer

May 28, 2009 - Stereotactic body radiotherapy (SBRT) when used to treat certain patients with non-small-cell lung cancer provided a 3-year local tumor control rate of 90 percent or higher with minor toxicity, reported Scandinavian researchers report in a May 4th online edition of the Journal of Clinical Oncology.

Lead investigator, Pia Baumann, a medical doctor at Karolinska University Hospital Solna, Stockholm, and colleagues conducted a phase II trial that included 40 patients with stage 1 tumors and 17 with stage 2 tumors who underwent SBRT every second day for a median of 5 days of treatment.

At 1 year, overall survival was 88 percent and cancer-specific survival was 93%. At 3 years, progression-free survival was 52%, overall survival was 60% and cancer-specific survival was 88%. There was no significant survival difference between patients with T1 and T2 tumors.

At a median follow-up of 35 months, 7 patients had died from lung cancer and 20 from concurrent disease. Estimated local control at 3 years was 92%. The estimated risk of failure due to local, regional or distant metastases was significantly greater in patients with T2 tumors than in those with T1 tumors (41% versus 18%).

The researchers suggest that based on these findings, SBRT "may even challenge surgery in operable instances."

SBRT is efficient in eradicating tumors with only limited side effects in patients with medically inoperable stage I non-small cell lung cancer, indicated Dr. Baumann. "SBRT is also useful for treating metastatic tumors in diverse organs."

Source: J Clin Oncol 2009;27.

For more information: jco.ascopubs.org

Related Content

Insightec Announces Expanded Reach of MR-Guided Focused Ultrasound
News | Focused Ultrasound Therapy | August 22, 2017
Insightec announced recently that worldwide adoption of magnetic resonance (MR)-guided focused ultrasound continues to...
UCLA Study Offers Roadmap to Personalized Therapies for Sarcoma
News | Oncology Diagnostics | August 22, 2017
A new UCLA study is the first to identify patient and tumor characteristics that predict the successful creation of...
Sponsored Content | Videos | Information Technology | August 22, 2017
Melissa Martin, MS, president of the American Association of Physicists in Medicine (AAPM), discusses her vision of t
Sponsored Content | Videos | Proton Therapy | August 21, 2017
Mark Pankuch, Ph.D., director of medical physics at the Northwestern Medicine Chicago Proton Center, discusses the cl
Summit Cancer Center-Boise Treats First Cancer Patients With Accuray Radixact System
News | Image Guided Radiation Therapy (IGRT) | August 21, 2017
Accuray Inc. and the Summit Cancer Center-Boise announced that the center is now treating patients with the Radixact...
MedStar Georgetown Proton Center Selects RayStation for Treatment Planning
News | Treatment Planning | August 17, 2017
August 17, 2017 — The proton center at MedStar Georgetown University Hospital will utilize RayStation for planning on
DOSIsoft Releases ISOgray Proton Therapy Treatment Planning System
Technology | Treatment Planning | August 15, 2017
DOSIsoft SA announced the official release, with CE marking, of ISOgray Treatment Planning System (TPS) release 4.3 for...
First Radixact Results Presented at AAPM 2017
News | Radiation Therapy | August 10, 2017
Accuray Inc. announced that the first studies validating the benefits of the Radixact System were presented at the 59th...
Clinical Data Supports Use of Xoft System for Endometrial Cancer
News | Brachytherapy Systems | August 03, 2017
Researchers presented clinical data supporting use of the Xoft Axxent Electronic Brachytherapy (eBx) System for the...
Overlay Init